ESSA PHARMA INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 USD | -0.65% |
|
-3.80% | -7.88% |
| Mar. 06 | Transcript : ESSA Pharma Inc. - Shareholder/Analyst Call | |
| Mar. 06 | Norway's wealth fund pushes for more women on emerging market company boards | RE |
Valuation
| Fiscal Period: Settembre | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 92.65 | 266.4 | 446.3 | 110.9 | 185 | 368.2 | - | - |
| Enterprise Value (EV) 1 | 92.65 | 266.4 | 446.3 | 110.9 | 185 | 368.2 | 368.2 | 368.2 |
| P/E ratio | -2.74 x | -6.93 x | -8.39 x | -2.3 x | -5.15 x | -7.66 x | -5.45 x | -4.23 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 48.8 x |
| EV / Revenue | - | - | - | - | - | - | - | 48.8 x |
| EV / EBITDA | -5,533,500 x | -8,705,617 x | - | - | - | - | - | - |
| EV / FCF | - | - | -13.9 x | -2.97 x | -6.3 x | -7.03 x | -3.38 x | -2.3 x |
| FCF Yield | - | - | -7.2% | -33.7% | -15.9% | -14.2% | -29.6% | -43.4% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,762 | 29,009 | 43,984 | 44,073 | 44,101 | 44,238 | - | - |
| Reference price 2 | 4.463 | 9.182 | 10.15 | 2.516 | 4.195 | 8.323 | 8.323 | 8.323 |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Settembre | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 7.55 |
| EBITDA | -16.74 | -30.6 | - | - | - | - | - | - |
| EBIT 1 | -16.77 | -30.74 | -46.8 | -50.52 | -43.61 | -55.34 | -88.2 | -128.5 |
| Operating Margin | - | - | - | - | - | - | - | -1,701.92% |
| Earnings before Tax (EBT) 1 | -13.66 | -30.22 | -46.42 | -48.13 | -36.07 | -48.24 | -78.83 | -112.1 |
| Net income 1 | -13.71 | -29.85 | -46.37 | -47.98 | -36.08 | -48.24 | -78.83 | -112.1 |
| Net margin | - | - | - | - | - | - | - | -1,485.05% |
| EPS 2 | -1.628 | -1.324 | -1.210 | -1.093 | -0.8143 | -1.086 | -1.526 | -1.966 |
| Free Cash Flow 1 | - | - | -32.11 | -37.35 | -29.36 | -52.41 | -108.9 | -159.9 |
| FCF margin | - | - | - | - | - | - | - | -2,118.14% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.61 | -11.53 | -14.9 | -11.95 | -9.733 | -10.57 | -10.97 | -11.92 | -9.701 | -10.21 | -12.9 | -14.8 | -17.36 | -25.76 | -29.83 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -10.74 | -11.54 | -14.1 | -11.41 | -8.734 | -9.063 | -9.428 | -9.765 | -7.438 | -8.015 | -11.5 | -13.12 | -15.58 | -25.76 | -29.83 |
| Net income 1 | -10.74 | -11.54 | -14.1 | -11.35 | -8.643 | -9.059 | -9.43 | -9.765 | -7.441 | -8.015 | -11.5 | -13.12 | -15.58 | -25.76 | -29.83 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2520 | -0.2665 | -0.3247 | -0.2571 | -0.1914 | -0.2017 | -0.2137 | -0.2274 | -0.1628 | -0.1882 | -0.2602 | -0.2942 | -0.3418 | -0.5690 | -0.6640 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/18/21 | 2/3/22 | 5/10/22 | 8/4/22 | 12/13/22 | 2/7/23 | 5/9/23 | 8/8/23 | 12/12/23 | 2/13/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -32.1 | -37.3 | -29.4 | -52.4 | -109 | -160 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.323
CAD
Average target price
27.08
CAD
Spread / Average Target
+225.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.88% | 269M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- EPIX Stock
- Financials ESSA Pharma Inc.
